Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Director · Chief Innovation Officer | May 27, 2025 | May 29, 2025 |
| SIGA TECHNOLOGIES INCSIGA · Entity 6205 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
OPKO HEALTH, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2035-05-26 | Direct | 437,500 |
Reported balance
After 2025-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-27 · Grant · Acquired 437,500 · Balance 437,500 F1: This option will vest in four equal annual installments beginning May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in four equal annual installments beginning May 27, 2026.
SIGA TECHNOLOGIES INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 73,754 |
Ending reported balance
After 2026-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-09 · Exercise / conversion · Acquired 24,116 · Balance 80,989 F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Row 2 · 2026-06-09 · Disposition to issuer · Disposed 7,235 · Balance 73,754 F2: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 11, 2025. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. |
| Restricted Stock UnitesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Exercise / conversion · Disposed 24,116 · Balance 0 F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,169 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 34,169 · Balance 34,169 F4: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 10,251 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the Board of Directors. F5: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis.
F2: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 11, 2025. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs.
F3: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders.
F4: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 10,251 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the Board of Directors.
F5: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:28 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001867450-26-000002 · ownership.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 01:14 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 34,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266390 · ownership.xml · derivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,169 Underlying: Common Stock, par value $.0001 per share · 34,169 shares Expires not disclosed F4 · derivative.exercise_price: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 10,251 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the Board of Directors. F5 · derivative.exercise_date: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders. F5 · derivative.expiration_date: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 01:14 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Unites · Derivative | 24,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266390 · ownership.xml · derivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 24,116 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 01:14 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Disposition to issuerCommon Stock, par value $.0001 per share | 7,235 | $4.39 | $31,761.65 |
DisclosureSEC source: 0001193125-26-266390 · ownership.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,754 F2 · kind: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 11, 2025. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 01:14 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 24,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-266390 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 12:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 5,353 | $4.67 | $24,998.51 |
DisclosureSEC source: 0000950170-25-090192 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,353 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:33 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087699 · ownership.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:29 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 24,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084856 · ownership.xml · derivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,116 Underlying: Common Stock, par value $.0001 per share · 24,116 shares Expires not disclosed F4 · derivative.exercise_price: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 7,235 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors. F5 · derivative.exercise_date: The RSUs fully vest on the date of the Company's 2026 annual meeting of stockholders. F5 · derivative.expiration_date: The RSUs fully vest on the date of the Company's 2026 annual meeting of stockholders. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:29 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084856 · ownership.xml · derivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 19,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were granted on June 11, 2024, and fully vested on the date of the Company's 2025 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs were granted on June 11, 2024, and fully vested on the date of the Company's 2025 annual meeting of stockholders. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:29 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Disposition to issuerCommon Stock, par value $.0001 per share | 5,725 | $6.22 | $35,609.50 |
DisclosureSEC source: 0000950170-25-084856 · ownership.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,873 F2 · kind: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 13, 2024. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:29 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 19,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-084856 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:02 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 437,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000950170-25-079104 · ownership.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2035-05-26 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 27, 2026. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 23:05 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 437,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-087030 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,579 F1 · security: Each restricted stock unit represents a contingent right to receive one share of OPKO common stock upon the vesting of the award. The restricted stock units vest 50% on the second anniversary of the grant date, then 25% on each of the following two years. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:39 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078173 · ownership.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:18 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073033 · ownership.xml · derivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,084 Underlying: Common Stock, par value $.0001 per share · 19,084 shares Expires not disclosed F4 · derivative.exercise_price: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 5,725 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors. F5 · derivative.exercise_date: The RSUs fully vest on the date of the Company's 2025 annual meeting of stockholders. F5 · derivative.expiration_date: The RSUs fully vest on the date of the Company's 2025 annual meeting of stockholders. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:18 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 24,712 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073033 · ownership.xml · derivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 24,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were granted on June 13, 2023, and fully vested on the date of the Company's 2024 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs were granted on June 13, 2023, and fully vested on the date of the Company's 2024 annual meeting of stockholders. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:18 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Disposition to issuerCommon Stock, par value $.0001 per share | 7,414 | $7.86 | $58,274.04 |
DisclosureSEC source: 0000950170-24-073033 · ownership.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,514 F2 · kind: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 15, 2023. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:18 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 24,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-073033 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 22:56 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 106,989 | $0.93 | $99,424.88 |
DisclosureSEC source: 0000950170-24-003699 · ownership.xml · nonDerivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 107,489 F2 · balance_after: Shares held by the Elizabeth G. Nabel ROTH Contributory IRA. Excludes 113,200 shares purchased in 2022. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Shares held by the Elizabeth G. Nabel ROTH Contributory IRA. Excludes 113,200 shares purchased in 2022. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 22:56 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 500 | $0.92 | $458.90 |
DisclosureSEC source: 0000950170-24-003699 · ownership.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 500 F2 · ownership.nature: Shares held by the Elizabeth G. Nabel ROTH Contributory IRA. Excludes 113,200 shares purchased in 2022. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 22:56 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 108,695 | $0.93 | $100,542.88 |
DisclosureSEC source: 0000950170-24-003699 · ownership.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 351,442 F1 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be dee admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 13:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-040130 · doc4.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:15 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 24,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037429 · doc4.xml · derivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,712 Underlying: Common Stock, par value $.0001 per share · 24,712 shares Expires not disclosed F4 · derivative.exercise_price: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 7,414 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors. F5 · derivative.exercise_date: The RSUs fully vest on the date of the Company's 2024 annual meeting of stockholders. F5 · derivative.expiration_date: The RSUs fully vest on the date of the Company's 2024 annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:15 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 14,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037429 · doc4.xml · derivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 14,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were granted on June 14, 2022, and fully vested on the date of the Company's 2023 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs were granted on June 14, 2022, and fully vested on the date of the Company's 2023 annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:15 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Disposition to issuerCommon Stock, par value $.0001 per share | 4,386 | $6.07 | $26,623.02 |
DisclosureSEC source: 0001209191-23-037429 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,216 F2 · kind: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 16, 2022. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:15 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 14,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-037429 · doc4.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:36 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-031030 · doc4.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 54,054 | $1.85 | $99,999.90 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 14 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 242,747 F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 20,009 | $1.85 | $36,960.62 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 13 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 188,693 F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 54,346 | $1.84 | $99,991.21 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 12 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 168,684 F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 34,338 | $1.84 | $63,113.24 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 11 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 114,338 F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 54,945 | $1.82 | $99,999.90 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 10 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,912,459 F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 26,407 | $1.85 | $48,852.95 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 9 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,912,459 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 28,538 | $1.82 | $51,939.16 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 8 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,886,052 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 10,928 | $1.83 | $19,998.24 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 7 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,079 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 19,475 | $1.83 | $35,619.78 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 6 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,151 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 79,334 | $1.82 | $144,387.88 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 5 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,676 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 27,624 | $1.81 | $49,999.44 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,342 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 27,777 | $1.80 | $49,998.60 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,718 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 3,185 | $1.79 | $5,710.71 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,941 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 19,285 | $1.78 | $34,327.30 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,756 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 12:05 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,480 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000899243-22-028202 · doc4.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2032-08-08 F1 · derivative.exercise_date: 33% of the shares underlying this option shall vest and become exercisable on August 8, 2023, with the remainder vesting in two (2) equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 80,000 | $2.47 | $197,600.00 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 8 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Nabel Family Investments LLC Disclosed balance after: 80,000 F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be dee admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 33,777 | $2.50 | $84,442.50 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 7 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the EGN 2021 TRUST Disclosed balance after: 19,857,514 F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 15,200 | $2.50 | $37,962.00 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 6 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the EGN 2021 TRUST Disclosed balance after: 19,823,737 F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 31,023 | $2.50 | $77,402.39 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 5 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the EGN 2021 TRUST Disclosed balance after: 19,808,537 F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 13,229 | $2.50 | $33,072.50 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the GJN 2021 TRUST Disclosed balance after: 19,857,514 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 65,280 | $2.50 | $163,193.47 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the GJN 2021 TRUST Disclosed balance after: 19,844,285 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:52 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 1,491 | $2.50 | $3,720.05 |
DisclosureSEC source: 0001209191-22-039341 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the GJN 2021 TRUST Disclosed balance after: 19,779,005 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:47 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 14,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037562 · doc4.xml · derivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,620 Underlying: Common Stock, par value $.0001 per share · 14,620 shares Expires not disclosed F4 · derivative.exercise_price: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 4,386 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors. F5 · derivative.exercise_date: The RSUs fully vest on the date of the Company's 2023 annual meeting of stockholders. F5 · derivative.expiration_date: The RSUs fully vest on the date of the Company's 2023 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.